Health Technology · Pharmaceuticals: Major · NSE: COHANCE · data 2026-10-09
Cohance Lifesciences Ltd
Health check: Weak (2/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹441
Market cap
₹16,932 cr
P/E
159.8
P/B
4.3
ROE
6.4%
ROCE
4.6%
Debt / equity
0.1
Dividend yield
0.00%
1-year return
-49.1%
52-week high
₹917.85
52-week low
₹266.7
Operating margin
5.8%
Growth
| Revenue (last 12 months) | ₹2,142 cr |
| Net profit (last 12 months) | ₹106 cr |
| Sales growth, 3 years (yearly) | 19.0% |
| Profit growth, 3 years (yearly) | -24.2% |
Chart patterns
- Double top — forming (key level ₹416.2)
Similar companies
PFIZER LIMITED (PFIZER) · OneSource Specialty Pharma Limited (ONESOURCE) · Alivus Life Sciences Ltd (ALIVUS) · Eris Lifesciences Ltd (ERIS) · Alembic Pharmaceuticals Limited (APLLTD)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open COHANCE in NSE Scanner →